Wed, Jan. 21, 8:53 AM
Dec. 18, 2014, 8:23 AM
- Merck (NYSE:MRK) acquires privately-held Lausanne, Switzerland-based Oncoethix for an upfront payment of $110M and up to an additional $265M in clinical and regulatory milestones.
- Oncoethix's lead product is OTX015, a BET bromodomain inhibitor (2,3,4) currently in Phase 1b development for the treatment of hematological malignancies and advanced solid tumors.
- Bromodomain proteins 2,3 and 4 are considered potential cancer targets because of their pivotal role in regulating the transcription of growth-promoting genes and cell cycle regulators. In experimental models, the inhibition of BRD2/3/4 produced a potent antiproliferative effect associated with cell cycle arrest and cellular senescence.
Dec. 16, 2014, 1:55 AM| 3 Comments
Dec. 8, 2014, 7:20 AM
- Merck (NYSE:MRK) acquires Cubist Pharmaceuticals (NASDAQ:CBST) for $102 per share in cash or ~$9.5B. The equity value is $8.4B plus $1.1B in debt.
- CBST +34.5% to $99.98, MRK +0.15% premarket
- Previously: Merck close to $7B deal to acquire Cubist Pharmaceuticals (Dec. 7, 2014)
Dec. 7, 2014, 5:27 AM
- Merck (NYSE:MRK) is in talks to buy Cubist Pharmaceuticals (NASDAQ:CBST), in a deal valued at more than $7B, Bloomberg reports.
- Merck would pay about $100 per share. An offer in that range would represent a 34% premium over Cubist’s closing price on Dec. 5.
- An agreement could be announced as early as this week.
Nov. 24, 2014, 8:40 AM
- Tetraphase Pharmaceuticals (NASDAQ:TTPH) is reportedly considering selling itself after being approached by interested suitors. Sources say the acquirer could be Acetelion (OTCPK:ALIOF) (OTC:ALIOY) or Roche (OTCQX:RHHBY).
- The attraction is Tetraphase's antibiotic eravacycline, currently in Phase 3 development. Both oral and IV formulations of the drug have demonstrated higher dose response rates than Johnson & Johnson's (NYSE:JNJ) Levaquin (levofloxacin) for the treatment of complicated urinary tract infections. In the Ignite-2 study, patients receiving 200 mg eravacycline IV-to-oral doses achieved a response rate of 70.8% while patients receiving 250 mg IV-to-oral doses achieved 64.3%, both significantly ahead of Levaquin's 52.2% response rate.
- A trial comparing eravacycline to Merck's (NYSE:MRK) Invanz (ertapenem) for the treatment of complicated intra-abdominal infections is underway.
- TTPH is up 18% premarket on light volume.
- Previously: Tetraphase completes eravacycline Phase 3 enrollment
Oct. 19, 2014, 9:49 AM| 2 Comments
Aug. 5, 2014, 7:46 AM
Jul. 21, 2014, 8:56 AM
- German private equity firm Aurelius has agreed to buy Reckitt Benckiser's (OTCPK:RBGLY) Scholl shoe business. The company is expecting the brand to expand internationally and maintain growth.
- Aurelius will acquire the international rights to the business, except for North and South America, which will go to Bayer (OTCPK:BAYRY) as part of its $14B purchase of Merck (NYSE:MRK).
- The deal is expected to close in the third quarter of 2014.
Jun. 20, 2014, 8:13 AM| 3 Comments
Jun. 16, 2014, 3:48 PM
- Merck (MRK -0.3%) shareholder Ronald Burns files suit (Burns vs Idenix Pharmaceuticals) attempting to block its $3.9B acquisition of Idenix (IDIX +1.4%) stating that the price undervalues IDIX. He cites IDIX's intrinsic value and a flawed process that prevents competing bids.
- The deal includes a no-solicitation clause, grants MRK the right to match any superior offer and stipulates a $115.6M termination fee. Mr. Burns alleges that these clauses virtually assure Merck gets the deal.
Jun. 12, 2014, 3:57 PM
- At an investors meeting in Los Angeles, Merck (MRK -0.9%) EVP and President, Merck Research Laboratories Roger Perlmutter, M.D., Ph.D., says the company will consider large acquisitions as way to expand its product portfolio rather than obtain drug-development technologies. He says Merck continues to have an appetite for deals following its recent buy of Idenix (IDIX +0.3%) for $3.85B.
Jun. 9, 2014, 7:59 AM
May. 13, 2014, 8:00 AM
- Merck (MRK) has agreed to sell some ophthalmology products to Santen Pharmaceutical (SNPHY) for $600M upfront plus milestone payments.
- The deal covers Japan, as well as "key markets" in Europe and Asia Pacific, with the products generating $400M in annual sales in those regions.
- The transaction follows Merck's sale of its U.S. ophthalmology business to Akorn Pharmaceuticals.
- Merck will continue to sell ophthalmology products in various markets, including Latin America, Canada, Australia, and EMEA. (PR)
May. 6, 2014, 6:13 AM
- A deal between the two had been tipped last last week.
- Merck's (MRK) consumer care business includes well-known brands like Claritin, Afrin, and Coppertone. "The combination of Merck Consumer Care's complementary portfolio of products and geographic reach with Bayer's will create a global consumer care business better positioned to serve consumers around the world," says Bayer (BAYZF, BAYRY) Chairman Dr. Marijn Dekkers.
- Merck CEO Kenneth Frazier: "By unlocking value in Merck Consumer Care, we’re able to further our goal of being the premier research-intensive biopharmaceutical company through targeted investments that strengthen our product portfolio and enhance our pipeline.”
- Source: Press Release
May. 1, 2014, 6:52 PM
- Bayer (BAYZF, BAYRY) is in exclusive talks to buy Merck's (MRK) consumer health business for ~$14B, and a deal announcement is likely in the next few days, Bloomberg reports.
- Reckitt Benckiser said yesterday it was no longer in active discussions for the business.
- A deal would strengthen MRK’s core drug business while aiding Bayer's consumer products line by adding brands including Claritin.
MRK vs. ETF Alternatives
Other News & PR